摘要
The whole field of hematological malignancies has experienced a huge breakthrough during the past 40 years.Major methodological progress in cytogenetics(e.g.,fluorescence in situ hybridization,FISH),immunophenotyping(e.g.,multicolor flow cytometers),and molecular biology(with the discovery of numerous tumor molecular markers by polymerase chain reaction and,more recently,next-generation sequencing)has paved the way for the new concept of detecting and monitoring undetectable minimal residual disease(uMRD)and the engineering of multiple new targeted therapies,such as tyrosine kinase inhibitors and various immunotherapies,including monoclonal antibodies combined or not with antitumor agents,bispecific T-cell-engaging(BiTE)antibodies and chimeric antigen receptor T(CAR-T)cells(Supplementary Text 1 online).
作者
Meng Lv
Norbert Claude Gorin
Xiao-Jun Huang
吕萌;Norbert Claude Gorin;黄晓军(Peking University People’s Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China;Department of Hematology and Cell Therapy,European Society for Blood and Marrow Transplantation Global Committee,Hôpital Saint-Antoine AP-HP,Paris Sorbonne University,Paris 75012,France;Peking-Tsinghua Center for Life Sciences,Beijing 100871,China)
基金
supported by the National Key R&D Program of China(2021YFA1100902 and 2017YFA0104500)
the National Natural Science Foundation of China(81930004 and 82070182)
Beijing Nova Program of Science and Technology(Z191100001119120)
Fund of China Scholarship Council(202106015007)。
